Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
Established in 2004, the company focuses on treatments for tumours and diabetes. It has launched two drugs so far - one for stomach diseases and the other for high blood pressure. It has a further eight...
India’s Innoven Capital, a joint venture between UOB and Temasek Holdings-owned Seviora Holdings, has fractionalised a USD 50m venture debt fund using blockchain and smart contracts.
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
Temasek Holdings, A91 Partners, and Kae Capital have invested USD 135m in Indian omnichannel wellness products retailer HealthKart.